Moreover, these strategies may develop tumor sensitivity to immunotherapy by reducing tumor-induced immune suppression, which is remarkably consistent with the context of Fn-driven immunosuppression and inflammation [144,153]. The gene discussed is FN1; the disease is neoplasm.